Share on StockTwits

Credit Suisse began coverage on shares of Dendreon (NASDAQ:DNDN) in a research note issued on Thursday. The firm set a “neutral” rating on the stock.

DNDN has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note on Thursday, August 14th. They now have a $1.50 price target on the stock. Separately, analysts at R. F. Lafferty downgraded shares of Dendreon from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 13th. Finally, analysts at Roth Capital reiterated a “sell” rating on shares of Dendreon in a research note on Tuesday, August 12th. Six research analysts have rated the stock with a sell rating and ten have issued a hold rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $2.18.

Shares of Dendreon (NASDAQ:DNDN) traded up 1.49% on Thursday, hitting $1.36. The stock had a trading volume of 270,827 shares. Dendreon has a one year low of $1.24 and a one year high of $3.52. The stock has a 50-day moving average of $1.76 and a 200-day moving average of $2.33. The company’s market cap is $211.4 million.

Dendreon (NASDAQ:DNDN) last announced its earnings results on Wednesday, August 20th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.18). On average, analysts predict that Dendreon will post $-0.76 earnings per share for the current fiscal year.

Dendreon Corporation (NASDAQ:DNDN) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.